<!DOCTYPE html><html>    <head>        <script type="text/javascript">
    var sampling = Math.random() < 0.001;
    var page_begintime = (+new Date());
    (sampling) && ((new Image()).src = "http://isdspeed.qq.com/cgi-bin/r.cgi?flag1=7839&flag2=7&flag3=8&15=1000&r=" + Math.random());

    var biz = "MzA4MjM1NjQxNw==";
    var sn = "db635a1154ef17313edf5cddbbbaa7a9";
    var mid = "202242762" || "";
    var idx = "1" || "" ;
    
    //辟谣需求
    var is_rumor = ""*1;
    var norumor = ""*1;
    if (!!is_rumor&&!norumor){
      if (!document.referrer || document.referrer.indexOf("mp.weixin.qq.com/mp/rumor") == -1){
        location.href = location.protocol + "//mp.weixin.qq.com/mp/rumor?action=info&__biz=" + biz + "&mid=" + mid + "&idx=" + idx + "&sn=" + sn + "#wechat_redirect";
      }
    }
</script>        <meta http-equiv="Content-Type" content="text/html; charset=utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=1.0,user-scalable=0" /><link rel="shortcut icon" type="image/x-icon" href="http://res.wx.qq.com/mmbizwap/zh_CN/htmledition/images/icon/common/favicon22c41b.ico"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black"><meta name="format-detection" content="telephone=no"><script type="text/javascript">
    var uin = "MTI3OTExNQ==";
    var key = "2f5eb01238e84f7ed9c3b8e57bdd2353d4cdd8a0b5a9632552ff0aef02f8767f3e0b74c69b9f6d351d1150edf53753cd";
    var pass_ticket = "04qVBZTGbZM91kmv3IOtfqAu19O6KOXFk7IEn+AZ4kk=";
</script>        <title>源正细胞</title>        <link rel="stylesheet" type="text/css" href="http://res.wx.qq.com/mmbizwap/zh_CN/htmledition/style/page/appmsg/page_mp_article_improve22f6d8.css"><style>        </style><!--[if lt IE 9]><link rel="stylesheet" type="text/css" href="http://res.wx.qq.com/mmbizwap/zh_CN/htmledition/style/page/appmsg/page_mp_article_improve_pc22ebff.css"><![endif]--><script type="text/javascript">
    document.domain = "qq.com";
</script>    </head>    <body id="activity-detail" class="zh_CN ">            <script type="text/javascript">
        var write_sceen_time = (+new Date());
        (sampling) && ((new Image()).src = "http://isdspeed.qq.com/cgi-bin/r.cgi?flag1=7839&flag2=7&flag3=8&16=1000&r=" + Math.random());
    </script>        <div id="js_cmt_more" class="discuss_container access" style="display:none;">        <div class="discuss_container_inner">            <h2 class="rich_media_title" id="activity-name">【精华】14种肿瘤抗体靶向药物，你都了解吗？</h2>            <div class="discuss_list_wrp">                <div class="line_tips_wrp">                    <span class="line_tips">精选评论<span class="error_tips" id="js_cmt_nofans3" style="display:none">关注该公众号可参与评论</span></span>                </div>                <p class="discuss_access_tips" id="js_cmt_addbtn3" style="display:none"><a href="#comment">写评论<img class="icon_edit" src="http://res.wx.qq.com/mmbizwap/zh_CN/htmledition/images/icon/appmsg/icon_edit227bf3.png" alt=""></a></p>                <ul class="discuss_list" id="js_cmt_morelist"></ul>            </div>            <div class="loadmore" id="js_cmt_more_loading">                <div class="tips_wrp">                    <img src="http://res.wx.qq.com/mmbizwap/zh_CN/htmledition/images/icon/common/icon_loading_white22c04a.gif" class="loading_icon icon_loading_white" alt="">                    <span class="tips">加载中</span>                </div>            </div>            <div class="loadmore with_line" id="js_cmt_more_end" style="display:none">                <div class="tips_wrp"><span class="tips">以上评论由公众帐号筛选后显示</span></div>            </div>        </div>    </div>        <div id="js_cmt_mine" class="discuss_container editing access" style="display:none;">        <div class="discuss_container_inner">            <h2 class="rich_media_title" id="activity-name">【精华】14种肿瘤抗体靶向药物，你都了解吗？</h2>            <div class="frm_textarea_box_wrp">                <span class="frm_textarea_box">                    <textarea id="js_cmt_input" class="frm_textarea" placeholder="评论将由公众帐号筛选后显示，对所有人可见。"></textarea>                </span>            </div>            <div class="discuss_btn_wrp"><a id="js_cmt_submit" class="btn btn_inline btn_primary btn_discuss btn_disabled" href="javascript:;">提交</a></div>            <div class="discuss_list_wrp" style="display:none">                <div class="line_tips_wrp">                    <span class="line_tips">我的评论</span>                </div>                <ul class="discuss_list" id="js_cmt_mylist"></ul>            </div>            <div class="wx_poptips" id="js_cmt_toast" style="display:none;">                <img alt="" class="icon_toast" src="data:image/png;base64,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">                <p class="toast_content">已评论</p>            </div>        </div>    </div>    <div id="js_article" class="rich_media">                <div id="js_top_ad_area" class="top_banner"></div>                        <div class="rich_media_inner">            <h2 class="rich_media_title" id="activity-name">                【精华】14种肿瘤抗体靶向药物，你都了解吗？             </h2>            <div class="rich_media_meta_list">                <em id="post-date" class="rich_media_meta rich_media_meta_text">2015-01-08</em>                                <em class="rich_media_meta rich_media_meta_text">作者：阳光明媚</em>                                <a class="rich_media_meta rich_media_meta_link rich_media_meta_nickname" href="javascript:void(0);" id="post-user">源正细胞</a>            </div>            <div id="page-content">                <div id="img-content">                                                                                                                                                                <div class="rich_media_content" id="js_content"><p style="white-space: normal;"><span style="color: rgb(0, 112, 192);"><strong>《科学》杂志在2013年9月份发了一篇综述，专门讲述肿瘤的抗体治疗，将目前常用的抗体靶向药物介绍的非常详细，我们翻译了最主要的内容给大家了解。</strong></span></p><p style="white-space: normal;"><strong style="font-size: 16px;"><span style="color: rgb(227, 108, 9);"><br  /></span></strong></p><p style="white-space: normal;"><strong style="font-size: 16px;"><span style="color: rgb(227, 108, 9);">1.西妥昔单抗（爱必妥）</span></strong></p><p style="white-space: normal;"><span style="font-size: 16px;">靶点：EGFR</span></p><p style="white-space: normal;">肿瘤类型：结直肠癌、头颈部肿瘤</p><p style="white-space: normal;">适应症：</p><p style="white-space: normal;">KRAS野生型、EGFR表达的转移性结直肠癌。联合FOLFIRI时可作为一线；联合伊立替康治疗那些单用伊立替康化疗难治的病人；单药治疗就是针对那些奥沙利铂和伊立替康为主的化疗已经失败了，或者对伊立替康不耐受的。</p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><span style="font-size: 16px;">头颈部鳞状细胞癌。联合放疗可作为局部晚期的初始治疗；联合铂类为主的治疗再加上5-FU可作为复发或转移性疾病的一线治疗；如果单药用呢，就适合那些铂类治疗已经失败了的复发或转移性的疾病。</span></p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><strong><span style="font-size: 16px; color: rgb(227, 108, 9);">2.帕尼单抗（Vectibix）</span></strong></p><p style="white-space: normal;"><span style="font-size: 16px;">靶点：EGFR</span></p><p style="white-space: normal;"><span style="font-size: 16px;">肿瘤类型：结直肠癌</span></p><p style="white-space: normal;"><span style="font-size: 16px;">适应症：在氟尿嘧啶、奥沙利铂和伊立替康为基础的方案中已经失败了，KRAS野生型、EGFR表达的mCRC</span></p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><strong><span style="font-size: 16px; color: rgb(227, 108, 9);">3.曲妥珠单抗（赫赛汀）</span></strong></p><p style="white-space: normal;"><span style="font-size: 16px;">靶点：HER2</span></p><p style="white-space: normal;"><span style="font-size: 16px;">肿瘤类型：乳腺癌、胃癌</span></p><p style="white-space: normal;"><span style="font-size: 16px;">适应症：</span></p><p style="white-space: normal;"><span style="font-size: 16px;">HER2过表达淋巴结阳性或阴性乳腺癌的辅助治疗。作为治疗方案的一部分，包括阿霉素，环磷酰胺以及紫杉醇或多西他赛；也可以联合多西他赛和卡铂；在蒽环类为基础的治疗之后可以单药使用。</span></p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><span style="font-size: 16px;">HER2过表达转移性乳腺癌。联合紫杉醇一线使用；单药治疗适用那些已经接受过一种或多种方案的转移性疾病。</span></p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><span style="font-size: 16px;">HER2过表达转移性胃癌或食管胃结合部癌，之前未接受过针对转移性疾病的治疗，可联合顺铂和卡培他滨或5-FU。</span></p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><strong><span style="font-size: 16px; color: rgb(227, 108, 9);">4.帕妥珠单抗（Pejeta）</span></strong></p><p style="white-space: normal;"><span style="font-size: 16px;">靶点：HER2</span></p><p style="white-space: normal;"><span style="font-size: 16px;">肿瘤类型：乳腺癌</span></p><p style="white-space: normal;"><span style="font-size: 16px;">适应症：HER2阳性转移性乳腺癌，之前未接受过抗HER2治疗或化疗，联合曲妥珠单抗和多西他赛使用。</span></p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><strong><span style="font-size: 16px; color: rgb(227, 108, 9);">5.T-DM1（Kadcyla）</span></strong></p><p style="white-space: normal;"><span style="font-size: 16px;">靶点：HER2</span></p><p style="white-space: normal;"><span style="font-size: 16px;">肿瘤类型：乳腺癌</span></p><p style="white-space: normal;"><span style="font-size: 16px;">适应症：HER2阳性转移性乳腺癌，之前接受过赫赛汀和紫杉醇化疗。</span></p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><strong><span style="font-size: 16px; color: rgb(227, 108, 9);">6.贝伐珠单抗（安维汀）</span></strong></p><p style="white-space: normal;"><span style="font-size: 16px;">靶点：VEGF</span></p><p style="white-space: normal;"><span style="font-size: 16px;">肿瘤类型：结直肠癌，非小细胞肺癌，恶性胶质瘤，肾癌</span></p><p style="white-space: normal;"><span style="font-size: 16px;">适应症：</span></p><p style="white-space: normal;"><span style="font-size: 16px;">转移性结直肠癌。联合静脉输注5-FU为基础的化疗进行一线或二线治疗；一线含贝伐珠单抗方案治疗进展后，联合氟尿嘧啶为基础的化疗进行二线治疗。</span></p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><span style="font-size: 16px;">晚期非鳞状非小细胞肺癌。联合卡铂和紫杉醇治疗之前未接受过治疗的晚期病人。</span></p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><span style="font-size: 16px;">转移性肾癌，和IFN-α联用。</span></p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><span style="font-size: 16px;">恶性胶质瘤，初始治疗后疾病进展时使用，单药使用。</span></p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><strong><span style="font-size: 16px; color: rgb(227, 108, 9);">7.依匹单抗（Yervoy）</span></strong></p><p style="white-space: normal;"><span style="font-size: 16px;">靶点：CTLA4</span></p><p style="white-space: normal;"><span style="font-size: 16px;">肿瘤类型：黑色素瘤</span></p><p style="white-space: normal;"><span style="font-size: 16px;">适应症：不可切除或转移性黑色素瘤，之前的系统性治疗失败或者不能耐受。</span></p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><strong><span style="font-size: 16px; color: rgb(227, 108, 9);">8.利妥昔单抗（美罗华）</span></strong></p><p style="white-space: normal;"><span style="font-size: 16px;">靶点：CD20</span></p><p style="white-space: normal;"><span style="font-size: 16px;">肿瘤类型：NHL，慢性淋巴细胞白血病</span></p><p style="white-space: normal;"><span style="font-size: 16px;">适应症：</span></p><p style="white-space: normal;"><span style="font-size: 16px;">非霍奇金淋巴瘤。复发或难治性，低度恶性或滤泡型，CD20阳性B细胞NHL，单药治疗；之前未接受过治疗的滤泡型CD20阳性B细胞NHL，联合一线化疗；利妥昔单抗联合化疗让病人达到完全或部分缓解后，单药维持治疗；疾病未进展、低度、CD20阳性B细胞NHL在一线CVP化疗后使用利妥昔单抗单药治疗；之前未经过治疗的弥漫性大B细胞CD20阳性NHL，联合CHOP或其他蒽环类为主的化疗方案。</span></p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><span style="font-size: 16px;">慢性淋巴细胞白血病。之前接受过或未接受过治疗的CD20阳性病人，联合氟达拉滨和环磷酰胺</span></p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><strong><span style="font-size: 16px; color: rgb(227, 108, 9);">9.Ofatumubab (Arzerra)</span></strong></p><p style="white-space: normal;"><span style="font-size: 16px;">靶点：CD20</span></p><p style="white-space: normal;">肿瘤类型：慢性淋巴细胞白血病</p><p style="white-space: normal;">适应症：慢性淋巴细胞白血病患者，使用氟达拉滨和阿仑单抗无效，可使用Ofatumubab单药治疗</p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><strong><span style="font-size: 16px; color: rgb(227, 108, 9);">10.替伊莫单抗（泽娃灵）</span></strong></p><p style="white-space: normal;">靶点：CD20</p><p style="white-space: normal;">肿瘤类型：低度或滤泡型B细胞NHL</p><p style="white-space: normal;">适应症：B细胞NHL（复发或难治性，低度，滤泡型，或利妥昔单抗无效）。通过一线化疗已经取得部分或者完全缓解的滤泡性非NHL患者的继续治疗。</p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><strong><span style="font-size: 16px; color: rgb(227, 108, 9);">11.托西莫单抗（百克沙）</span></strong></p><p style="white-space: normal;">靶点：CD20</p><p style="white-space: normal;">肿瘤类型：低度或滤泡型B细胞NHL</p><p style="white-space: normal;">适应症：CD20阳性，复发或难治性，低度，滤泡性或转化的NHL，在利妥昔单抗治疗期间或治疗后疾病进展，包括利妥昔单抗难治的NHL。</p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><strong><span style="font-size: 16px; color: rgb(227, 108, 9);">12.阿仑单抗（Campath)</span></strong></p><p style="white-space: normal;">靶点：CD52</p><p style="white-space: normal;">肿瘤类型：慢性淋巴细胞白血病</p><p style="white-space: normal;">适应症：单药治疗B细胞慢性淋巴细胞白血病</p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><strong><span style="font-size: 16px; color: rgb(227, 108, 9);">13.Brentuximab vedotin（Adcetris）</span></strong></p><p style="white-space: normal;">靶点：CD30</p><p style="white-space: normal;">肿瘤类型：霍奇金淋巴瘤</p><p style="white-space: normal;">适应症：自体干细胞移植治疗失败，或不符合自体干细胞移植条件，经过至少两项多药物化疗无效的霍奇金淋巴瘤患者；或者经过至少一项多药物化疗治疗失败的系统性间变性大细胞淋巴瘤患者。</p><p style="white-space: normal;"><span style="font-size: 16px;"><br  /></span></p><p style="white-space: normal;"><strong><span style="font-size: 16px; color: rgb(227, 108, 9);">14.吉姆单抗（Mylotarg）</span></strong></p><p style="white-space: normal;">靶点：CD33</p><p style="white-space: normal;">肿瘤类型：急性髓细胞白血病</p><p style="white-space: normal;">适应症：2010年6月撤市。之前是治疗CD33阳性的第一次复发的急性髓细胞白血病，患者年龄60岁及以上，或者不能接受其他细胞毒化疗。</p><p style="white-space: normal;"><strong style="font-size: 16px;">源正细胞微信平台</strong></p><p style="white-space: normal;"><strong>来源：</strong>医脉通</p><p style="white-space: normal;"><strong>主编：</strong>周向军  </p><p style="white-space: normal;"><strong>E-mail:</strong>joe@thyx.com</p><p style="white-space: normal;"><strong>编辑部主任：</strong>杨粉娣</p><p style="white-space: normal;"><strong>E-mail</strong>:yangfd@thyx.com  </p><p style="white-space: normal;"><img data-src="http://mmbiz.qpic.cn/mmbiz/L74RXJGu4arvDFeptrrdDStibmgDgR9Lzia4C9QaWjYq6Ay4dtpH0UktdbeiascVR2oWmBViagbwthibd5NPWS9ic9ug/0" data-ratio="0.7813121272365805" data-w=""  /></p></div>                    <script type="text/javascript">
                        var first_sceen__time = (+new Date());
                    </script>                    <link rel="stylesheet" type="text/css" href="http://res.wx.qq.com/mmbizwap/zh_CN/htmledition/style/page/appmsg/page_mp_article_improve_combo22ebff.css">                                        <div class="rich_media_tool" id="js_toobar">                                                <div id="js_read_area" class="media_tool_meta link_primary meta_primary" style="display:none;">阅读 <span id="readNum"></span></div>                        <a style="display:none;" class="media_tool_meta meta_primary link_primary meta_praise" href="javascript:void(0);" id="like">                            <i class="icon_praise_gray"></i><span class="praise_num" id="likeNum"></span>                        </a>                        <a id="js_report_article" class="media_tool_meta link_primary meta_extra" href="javascript:void(0);">举报</a>                    </div>                </div>                                <div id="js_bottom_ad_area"></div>                                <div id="js_iframetest" style="display:none;"></div>                                                           </div>            <div id="js_pc_qr_code" class="qr_code_pc_outer" style="display:none;">                <div class="qr_code_pc_inner">                    <div class="qr_code_pc">                        <img id="js_pc_qr_code_img" class="qr_code_pc_img">                        <p>微信扫一扫<br>获得更多内容</p>                    </div>                </div>            </div>        </div>    </div>                <script>window.moon_map = {"a/gotoappdetail.js":"/mmbizwap/zh_CN/htmledition/js/a/gotoappdetail22c04a.js","a/ios.js":"/mmbizwap/zh_CN/htmledition/js/a/ios224ef3.js","a/android.js":"/mmbizwap/zh_CN/htmledition/js/a/android22772d.js","a/profile.js":"/mmbizwap/zh_CN/htmledition/js/a/profile224ef3.js","biz_common/utils/url/parse.js":"/mmbizwap/zh_CN/htmledition/js/biz_common/utils/url/parse224ef3.js","biz_common/utils/report.js":"/mmbizwap/zh_CN/htmledition/js/biz_common/utils/report224ef3.js","biz_common/utils/cookie.js":"/mmbizwap/zh_CN/htmledition/js/biz_common/utils/cookie224ef3.js","appmsg/like.js":"/mmbizwap/zh_CN/htmledition/js/appmsg/like224ef3.js","appmsg/a.js":"/mmbizwap/zh_CN/htmledition/js/appmsg/a22ec5d.js","biz_common/tmpl.js":"/mmbizwap/zh_CN/htmledition/js/biz_common/tmpl224ef3.js","biz_common/dom/class.js":"/mmbizwap/zh_CN/htmledition/js/biz_common/dom/class224ef3.js","biz_wap/utils/ajax.js":"/mmbizwap/zh_CN/htmledition/js/biz_wap/utils/ajax22589f.js","biz_common/utils/string/html.js":"/mmbizwap/zh_CN/htmledition/js/biz_common/utils/string/html224ef3.js","biz_common/ui/imgonepx.js":"/mmbizwap/zh_CN/htmledition/js/biz_common/ui/imgonepx224ef3.js","biz_common/dom/attr.js":"/mmbizwap/zh_CN/htmledition/js/biz_common/dom/attr22f190.js","appmsg/report.js":"/mmbizwap/zh_CN/htmledition/js/appmsg/report22f190.js","appmsg/report_and_source.js":"/mmbizwap/zh_CN/htmledition/js/appmsg/report_and_source224ef3.js","appmsg/share.js":"/mmbizwap/zh_CN/htmledition/js/appmsg/share224ef3.js","appmsg/comment.js":"/mmbizwap/zh_CN/htmledition/js/appmsg/comment22dbe5.js","appmsg/page_pos.js":"/mmbizwap/zh_CN/htmledition/js/appmsg/page_pos22f190.js","appmsg/cdn_speed_report.js":"/mmbizwap/zh_CN/htmledition/js/appmsg/cdn_speed_report224ef3.js","appmsg/iframe.js":"/mmbizwap/zh_CN/htmledition/js/appmsg/iframe22c41c.js","appmsg/review_image.js":"/mmbizwap/zh_CN/htmledition/js/appmsg/review_image224ef3.js","appmsg/outer_link.js":"/mmbizwap/zh_CN/htmledition/js/appmsg/outer_link224ef3.js","biz_wap/jsapi/core.js":"/mmbizwap/zh_CN/htmledition/js/biz_wap/jsapi/core22589f.js","biz_wap/utils/mmversion.js":"/mmbizwap/zh_CN/htmledition/js/biz_wap/utils/mmversion224ef3.js","biz_common/dom/event.js":"/mmbizwap/zh_CN/htmledition/js/biz_common/dom/event22772d.js","appmsg/async.js":"/mmbizwap/zh_CN/htmledition/js/appmsg/async22ec5d.js","biz_wap/ui/lazyload_img.js":"/mmbizwap/zh_CN/htmledition/js/biz_wap/ui/lazyload_img22f7a3.js","biz_common/log/jserr.js":"/mmbizwap/zh_CN/htmledition/js/biz_common/log/jserr22589f.js","appmsg/index.js":"/mmbizwap/zh_CN/htmledition/js/appmsg/index22f190.js"};window.moon_crossorigin = true;</script><script type="text/javascript" src="http://res.wx.qq.com/mmbizwap/zh_CN/htmledition/js/biz_wap/moon224ef3.js" crossorigin></script>    <script id="t_cmt" type="text/html">
        <li class="discuss_item">
            <span class="discuss_time"><#=time#></span>
            <div class="user_info">
                <strong class="nickname"><#=nick_name#></strong>
                <img class="avatar" src="<#=logo_url#>">
            </div>
            <div class="discuss_message">
                <span class="discuss_status"><#=status#></span>
                <#=content#>
            </div>
        </li>
    </script>  <script id="t_ad" type="text/html">
    <div class="rich_media_extra" id="gdt_area">
        <# if(pos_type==0){ #>
        <div class="line_tips_wrp">
            <span class="line_tips">推广</span>
        </div>
        <# } #>
        <div class="js_ad_link extra_link" data-type="<#=type#>" data-url="<#=url#>" data-rl="<#=rl#>"  data-aid="<#=aid#>" data-pt="<#=pt#>" data-tid="<#=traceid#>" data-gid="<#=group_id#>" data-apurl="<#=apurl#>">
            <# if(pt==1){ #>
            <#=hint_txt#>
            <img class="icon_arrow_gray" src="http://res.wx.qq.com/mmbizwap/zh_CN/htmledition/images/icon/common/icon_arrow_gray1ef6d4.png">
            <img class="icon_loading_white icon_after" style="display:none;" id="loading_<#=traceid#>" src="http://res.wx.qq.com/mmbizwap/zh_CN/htmledition/images/icon/common/icon_loading_white22c04a.gif">
            <# }else if(pt==2){ #>
            <img class="appmsg_banner" src="<#=image_url#>">
            <i class="promotion_tag"></i>
            <# }else if(pt==7){ #>
            
            <div class="preview_group preview_card">
                <div class="preview_group_inner card_inner">
                    <div class="preview_group_info">
                        <strong class="preview_group_title2"><#=hint_txt#></strong>
                        <div class="preview_group_desc"><#=ad_desc#></div>
                        <img src="<#=image_url#>" alt="" class="preview_card_avatar">
                    </div>
                </div>                        
            </div>
            <# }else if(pt==100){ #>
            <div class="preview_group">
                <div class="preview_group_inner">
                    <div class="preview_group_info append_btn">
                        <strong class="preview_group_title"><#=biz_info.nick_name#></strong>
                        <div class="preview_group_desc"><#=hint_txt#></div>
                        <# if(!!biz_info.head_img){ #>
                        <img src="<#=biz_info.head_img#>" alt="" class="preview_group_avatar br_radius">
                        <# }else{ #>
                        <img class="preview_group_avatar br_radius" src="http://mmbiz.qpic.cn/mmbiz/a5icZrUmbV8p5jb6RZ8aYfjfS2AVle8URwBt8QIu6XbGewB9wiaWYWkPwq4R7pfdsFibuLkic16UcxDSNYtB8HnC1Q/0" alt="<#=biz_info.nick_name#>">
                        <# } #>                                 
                    </div>
                    <div class="preview_group_opr">
                        <a id="viewProfile" <# if(biz_info.is_subscribed == 0){ #>style="display:none"<# } #> class="btn btn_inline btn_primary js_ad_btn" href="javascript:void(0);">查看</a>
                        <a id="addContact" data-url="<#=url#>" data-type="<#=type#>" data-tid="<#=traceid#>" data-rl="<#=rl#>" <# if(biz_info.is_subscribed ==1){ #>style="display:none"<# } #> class="btn btn_inline btn_primary js_ad_btn" href="javascript:void(0);">关注</a>
                    </div>
                </div>
            </div>
            <# }else if(pt==102){ #>
            <div class="preview_group">
                <div class="preview_group_inner">
                    <div class="preview_group_info append_btn">
                        <strong class="preview_group_title"><#=app_info.app_name#></strong>
                        <div class="preview_group_desc"><#=hint_txt#></div>
                        <img src="<#=app_info.icon_url#>" alt="" class="preview_group_avatar br_radius">
                    </div>
                    <div class="preview_group_opr">
                        <a id="js_app_action" class="btn btn_inline btn_primary js_ad_btn btn_download" href="javascript:void(0);">下载</a>
                    </div>
                </div>
            </div>
            <# }else if(pt==101){ #>
            <div class="preview_group preview_card">
                <div class="preview_group_inner card_inner">                            
                    <div class="preview_group_info append_btn">
                        <strong class="preview_group_title"><#=app_info.app_name#></strong>
                        <div class="preview_group_desc"><#=hint_txt#></div>
                        <img src="<#=app_info.icon_url#>" alt="" class="preview_card_avatar">                               
                    </div>
                    <div class="preview_group_opr">
                        <a href="javascript:void(0);" id="js_app_action" class="btn btn_inline btn_primary js_ad_btn">下载</a>
                    </div>
                </div>                        
            </div>
            <# }else if(pt==103||pt==104){ #>
            <div class="preview_group obvious_app">
                <div class="preview_group_inner">
                    <div class="pic_app">
                        <img src="<#=image_url#>" alt="">
                    </div>
                    <div class="info_app">
                        <p class="name_app"><#=app_info.app_name#></p>
                        <# if(pt==103){ #>
                        <p class="profile_app"><span class="fun_exp"><#=app_info._category#></span><em>|</em><span class="compacity"><#=app_info._app_size#></span></p>
                        <# } else if(pt==104){ #>
                        <p class="profile_app"><span class="fun_exp"><#=app_info._app_size#></span><em>|</em><span class="compacity"><#=app_info._down_count#></span></p>
                        <# } #>
                        <div class="dm_app">
                            <a href="javascript:void(0);" id="js_appdetail_action" class="ad_btn btn_download js_ad_btn">下载</a>
                            <p class="extra_info">来自<# if(pt==103){ #>Appstore<# }else{ #>腾讯应用宝<# } #></p>
                        </div>
                    </div>
                </div>            
            </div>
            <# } #>
        </div>
    </div>
  </script>  <script type="text/javascript">
      var tid = "";
      var aid = "";
      var appuin = "MzA4MjM1NjQxNw==";

      //下边这两个值为什么调转过来呢？是因为要跟推广页的字段保持一致。。坑爹
      var source = "";
      var scene = 75;
      
      var itemidx = "";
      var nickname = "源正细胞";
      var ct = "1420688732";
      var user_name = "gh_9e3da777d848";
      var fakeid   = "MTI3OTExNQ==";
      var version   = "";
      var is_limit_user   = "0";
      var msg_title = "【精华】14种肿瘤抗体靶向药物，你都了解吗？";
      var msg_desc = "《科学》杂志在2013年9月份发了一篇综述，专门讲述肿瘤的抗体治疗，将目前常用的抗体靶向药物介绍的非常详细，";
      var msg_cdn_url = "http://mmbiz.qpic.cn/mmbiz/L74RXJGu4apxPqBjuQnwQWelpXvxDBKkXMk55jbfErpAzic0f4VIVI2WP1tUHPUib6EwXqG6bcFl6egCRwnefHxg/0";
      var msg_link = "http://mp.weixin.qq.com/s?__biz=MzA4MjM1NjQxNw==&amp;mid=202242762&amp;idx=1&amp;sn=db635a1154ef17313edf5cddbbbaa7a9#rd";
      var user_uin = "1279115"*1;
      var msg_source_url = '';
      var networkType;
      var appmsgid = '' || '202242762';
      var comment_id = "0" * 1;
      var comment_enabled = "" * 1;

      var devicetype = "iMac&amp;nbsp;MacBookPro10,1&amp;nbsp;OSX&amp;nbsp;OSX&amp;nbsp;10.10.1&amp;nbsp;build(14B25)";

      
            seajs.use("appmsg/index.js");
  </script>    </body></html>